Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumimasa Nagai

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
The Lancet. Oncology|March 4, 2021
Current situation of oncology biosimilars in JapanSumimasa Nagai
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 9, 2020
[Pharmaceutical approval process of drugs for hematological malignancies: current situations in Japan]Sumimasa Nagai
International Journal of Molecular Sciences|August 7, 2019
Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and JapanSumimasa Nagai
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 3, 2015
[Exploratory biomarker analyses and companion diagnostics]Sumimasa Nagai
The Lancet. Haematology|September 24, 2021
Regulatory hurdles for CAR T-cell therapy in JapanSumimasa Nagai
Clinical Therapeutics|December 12, 2018
Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in JapanSumimasa Nagai, Daisuke Sugiyama
Current Gene Therapy|April 7, 2017
New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy ProductsSumimasa Nagai, Keiya Ozawa
Investigational New Drugs|August 20, 2016
Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projectsSumimasa Nagai, Keiya Ozawa
International Journal of Hematology|April 17, 2016
Regulatory approval pathways for anticancer drugs in Japan, the EU and the USSumimasa Nagai, Keiya Ozawa
British Journal of Haematology|March 29, 2016
Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the USSumimasa Nagai, Keiya Ozawa
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
The Lancet. Oncology|March 4, 2021
Current situation of oncology biosimilars in JapanSumimasa Nagai
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 9, 2020
[Pharmaceutical approval process of drugs for hematological malignancies: current situations in Japan]Sumimasa Nagai
International Journal of Molecular Sciences|August 7, 2019
Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and JapanSumimasa Nagai
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 3, 2015
[Exploratory biomarker analyses and companion diagnostics]Sumimasa Nagai
The Lancet. Haematology|September 24, 2021
Regulatory hurdles for CAR T-cell therapy in JapanSumimasa Nagai
Clinical Therapeutics|December 12, 2018
Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in JapanSumimasa Nagai, Daisuke Sugiyama
Current Gene Therapy|April 7, 2017
New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy ProductsSumimasa Nagai, Keiya Ozawa
Investigational New Drugs|August 20, 2016
Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projectsSumimasa Nagai, Keiya Ozawa
International Journal of Hematology|April 17, 2016
Regulatory approval pathways for anticancer drugs in Japan, the EU and the USSumimasa Nagai, Keiya Ozawa
British Journal of Haematology|March 29, 2016
Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the USSumimasa Nagai, Keiya Ozawa
Pageof 5